论文部分内容阅读
Introduction: The dose of anthracyclines in the adjuvant treatment of the breast cancer is relatively standardized in the western world.In Turkey, we attempt to treat the patients with a similar dose and schedule outlined in these studies.Through the years, during interpersonal communication in between medical oncologists, we observe that the toleration of the Turkish patients to anthracyclines is poorer than what has been reported in the western literature.We are concerned that this poor toleration causes dose reductions and as a result, the Turkish patients receive lower than ideal cumulative doses of anthracyclines.Material & Methods: We studied the cumulative anthracycline doses in breast cancer patients treated in Marmara University Hospital.Only patients treated with epirubucin 90-100 mg/m2in combination with cyclophosphamide and 5Fluoruracil are included for homogeneity of data.The degree and.the.type of toxicity causing the dose reduction are also noted.